Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Givinostat Hydrochloride

FDA-approved product (suspension, oral), marketed as Duvyzat.

Registered studies
23
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Givinostat Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Duchenne muscular dystrophy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for disorders of the musculo-skeletal system
FDA pharmacologic class
Histone Deacetylase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Givinostat Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Givinostat Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

    NCT00792506 · start 2008-10

    Registered record
    Registry ID
    NCT00792506
    Conditions
    Multiple Myeloma
    Interventions
    ITF2357
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2010-07
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionITF2357
    PhasePhase 2
    Registry statusTerminated

  • Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

    NCT00792467 · start 2008-02

    Registered record
    Registry ID
    NCT00792467
    Conditions
    Hodgkin's Lymphoma
    Interventions
    ITF2357
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin's Lymphoma
    InterventionITF2357
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

    NCT00792831 · start 2008-02

    Registered record
    Registry ID
    NCT00792831
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    ITF2357
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-02
    Completion
    2009-04
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionITF2357
    PhasePhase 2
    Registry statusTerminated

  • Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

    NCT00606307 · start 2007-12

    Registered record
    Registry ID
    NCT00606307
    Conditions
    Myeloproliferative Diseases
    Interventions
    ITF2357
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-12
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeloproliferative Diseases
    InterventionITF2357
    PhasePhase 2
    Registry statusCompleted

  • Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

    NCT00792740 · start 2007-10-22

    Registered record
    Registry ID
    NCT00792740
    Conditions
    Crohn's Disease
    Interventions
    ITF2357; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2007-10-22
    Completion
    2009-03-11
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionITF2357; Placebo
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

    NCT00496431 · start 2007-05

    Registered record
    Registry ID
    NCT00496431
    Conditions
    Hodgkin's Lymphoma
    Interventions
    histone deacetylase inhibitor (ITF2357)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2007-05
    Completion
    2009-03
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin's Lymphoma
    Interventionhistone deacetylase inhibitor (ITF2357)
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis

    NCT00570661 · start 2006-09-12

    Registered record
    Registry ID
    NCT00570661
    Conditions
    Active Systemic; Onset Juvenile Idiopathic Arthritis
    Interventions
    ITF2357
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-09-12
    Completion
    2013-06-10
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActive Systemic; Onset Juvenile Idiopathic Arthritis
    InterventionITF2357
    PhasePhase 2
    Registry statusCompleted

  • The Efficacy and Safety of ITF2357 in AIS

    NCT00442182 · start 2006-09

    Registered record
    Registry ID
    NCT00442182
    Conditions
    Autoinflammatory Syndromes; HIDS; TRAPS; Schnitzler's Syndrome
    Interventions
    ITF2357
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2006-09
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutoinflammatory Syndromes; HIDS; TRAPS; Schnitzler's Syndrome
    InterventionITF2357
    PhasePhase 2
    Registry statusUnknown